Analyzing Spyre Therapeutics (SYRE) & Its Rivals

Spyre Therapeutics (NASDAQ:SYRE) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Spyre Therapeutics to similar businesses based on the strength of its dividends, institutional ownership, valuation, analyst recommendations, profitability, risk and earnings.

Profitability

This table compares Spyre Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-35.97%	-27.67%
Spyre Therapeutics Competitors	-12,285.98%	-196.04%	-30.61%

Analyst Ratings

This is a summary of recent recommendations and price targets for Spyre Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1	1	13	2	2.94
Spyre Therapeutics Competitors	9858	15137	45528	1590	2.54

Spyre Therapeutics currently has a consensus price target of $110.53, suggesting a potential upside of 5.79%. As a group, “Biotechnology” companies have a potential upside of 99.99%. Given Spyre Therapeutics’ peers higher probable upside, analysts plainly believe Spyre Therapeutics has less favorable growth aspects than its peers.

Institutional & Insider Ownership

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Spyre Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spyre Therapeutics	$890,000.00	-$155.20 million	-38.13
Spyre Therapeutics Competitors	$702.95 million	$10.43 million	-15.13

Spyre Therapeutics’ peers have higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Spyre Therapeutics has a beta of 3.24, suggesting that its stock price is 224% more volatile than the S&P 500. Comparatively, Spyre Therapeutics’ peers have a beta of 1.15, suggesting that their average stock price is 15% more volatile than the S&P 500.

Summary

Spyre Therapeutics beats its peers on 9 of the 13 factors compared.

Spyre Therapeutics Company Profile

Spyre Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its research focuses on therapies designed to target immune pathways involved in these conditions. The company’s pipeline includes investigational antibodies targeting TL1A, IL-23 and integrin ?4?7, as well as potential combinations of these approaches. Spyre has no approved products, and its candidates remain in development.